Effects of Homocysteine on the Dopaminergic System and Behavior in Rodents
Section snippets
INTRODUCTION
Parkinson's disease (PD) is a progressive neurological disorder resulted from dopaminergic cell death and dopamine depletion (Hornykiewicz, 1966). Since the etiology of PD remains to be elucidated, the strategy of current treatments of PD patients is symptomatic with efforts to slowdown the progression of the disease. l-3,4-Dihydroxyphenylalanine (levodopa) is a precursor of dopamine and represents the most effective medication for PD treatment.
When levodopa serves as a precursor of dopamine,
Animals
Male Sprague–Dawley rats weighing 180–200 g and male C57BL/6 mice 4 weeks old were purchased from Harlan (Indianapolis, IN). Animals were kept in the animal care facility until the beginning of experiments and had access to food and water ad libitum, under a 12 h light/dark cycle. Temperature was maintained at 21 ± 1 °C.
Chemicals
Homocysteine, 3-O-methyldopa, adenosine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), tri-n
Effects of Homocysteine, Adenosine, and 3-OMD on Dopamine Turnover in Rat Brain Striatum
SAM-dependent methylation of levodopa results in the production of 3-OMD as well as S-adenosylhomocysteine (SAH) which is readily hydrolyzed by SAH hydrolase to adenosine and homocysteine (Fig. 1). The present study was focused on homocysteine effects to determine the possible role of elevated homocysteine in pathological conditions such as PD with levodopa treatment. Three possible metabolites of levodopa, homocysteine, 3-OMD and adenosine, were also tested.
Sprague–Dawley male rats were
DISCUSSION
The findings of our study reveal that homocysteine significantly decreased locomotor activities in rats and mice. Homocysteine also caused severe reduction of dopamine turnover in the striatum and decreased TH immunoreactivity in substantia nigra of mouse brain after chronic exposure, implicating that elevated homocysteine could cause harmful impacts on the dopaminergic nervous system. These results indicate that elevated homocysteine could be associated with the complications of levodopa
ACKNOWLEDGEMENTS
This work was supported by grants received from the National Institutes of Health (RO1 28432, RR 03020, and GM 08111).
REFERENCES (49)
Neuropharmacology of S-adenosyl-l-methionine
Am J Med
(1987)- et al.
Levels of l-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease
Exp Neurol
(1997) Anticonvulsant action of both NMDA and non-NMDA receptor antagonists against seizures induced by homocysteine in immature rats
Exp Neurol
(1997)- et al.
Behavioral and neurochemical changes in folate-deficient mice
Physiol Behav
(1995) - et al.
Measurement of total plasma and cerebrospinal fluid homocysteine by fluorescence following high-performance liquid chromatography and precolumn derivatization with O-phthaldialdehyde
J Chromatogr
(1992) - et al.
l-Homocysteate is a potent neurotoxin on cultured cortical neurons
Brain Res
(1987) - et al.
Involvement of N-methyl-d-aspartate receptor and free radical in homocysteine-mediated toxicity on rat cerebellar granule cells in culture
Neurosci Lett
(1996) - et al.
Effects of l-dopa treatment on methylation in mouse brain: implications for the side effects of l-dopa
Life Sci
(2000) - et al.
Homocysteine induces cell death of rat astrocytes in vitro
Neurosci Lett
(2003) - et al.
On–off effects in patients with Parkinson's disease on chronic levodopa therapy
Lancet
(1976)
Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders
Trends Neurosci
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat
Neurobiol Dis
Amino acids as dietary excitotoxins: a contribution to understanding neurodegenerative disorders
Brain Res Brain Res Rev
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease
Lancet
Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease
Neurosci Lett
Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men
Lancet
Dopa and 3-O-methyldopa in cerebrospinal fluid of Parkinsonism patients during treatment with oral l-dopa
Clin Chim Acta
Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury
Thromb Res
l-Dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase
Exp Neurol
Sulfate and cysteine levels in the plasma of patients with Parkinson's disease
Neurotoxicology
Homocysteine and risk of cardiovascular disease
J Thromb Thrombolysis
Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase
J Pharmacol Exp Ther
The effects of l-dopa on the activity of methionine adenosyltransferase: relevance to l-dopa therapy and tolerance
Neurochem Res
Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam study
Arch Intern Med
Cited by (91)
Lactogenesis factors in the Asian population
2024, Clinica Chimica ActaPolyneuropathy in levodopa-treated Parkinson's patients
2016, Journal of the Neurological SciencesOxidative stress and mitochondrial dysfunction are the underlying events of dopaminergic neurodegeneration in homocysteine rat model of Parkinson's disease
2016, Neurochemistry InternationalCitation Excerpt :Our results that unilateral intranigral infusion of Hcy causes motor abnormalities, reduction of striatal dopamine level and degeneration of midbrain dopaminergic neurons (Fig. 2), which are similar to that in PD, are consistent with the earlier report (Chandra et al., 2006). Elevated Hcy levels in PD patients with or without l-DOPA therapy (Kuhn et al., 1998; Louis et al., 2007; Zoccolella et al., 2010; Hu et al., 2013) is of great concern as several independent studies have reported Hcy as a putative neurotoxin to dopaminergic neurons (Chandra et al., 2006; Duan et al., 2002; Lee et al., 2005). Intranigral or intrastriatal injection of Hcy was reported to exacerbate dopamine loss, dopaminergic neuronal loss and motor dysfunction in rodent model of PD; however Hcy alone failed to show any significant effect (Duan et al., 2002).
L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room
2016, Biochimica et Biophysica Acta - General Subjects